Cargando…
Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage
BACKGROUND: Although evidence suggests that stage of disease may influence costs associated with non-small cell lung cancer (NSCLC), there remains a relative paucity of data on the financial burden incurred directly by patients and their informal caregivers as they progress through the disease cours...
Autores principales: | Wood, Robert, Taylor-Stokes, Gavin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408828/ https://www.ncbi.nlm.nih.gov/pubmed/30849964 http://dx.doi.org/10.1186/s12885-019-5428-4 |
Ejemplares similares
-
The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden
por: Wood, Robert, et al.
Publicado: (2019) -
Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe
por: Moore, Adam, et al.
Publicado: (2022) -
Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden
por: Criss, Steven D., et al.
Publicado: (2020) -
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs
por: Apple, Jon, et al.
Publicado: (2023) -
Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe
por: Divajeva, Diana, et al.
Publicado: (2014)